



Title	Neutrophil extracellular trap formation and deoxyribonuclease I activity in patients with otitis media with antineutrophil cytoplasmic antibody-associated vasculitis
Author(s)	Morita, Shinya; Nakamaru, Yuji; Fukuda, Atsushi et al.
Citation	International archives of allergy and immunology, 185(8), 810-819 https://doi.org/10.1159/000537927
Issue Date	2024-08-01
Doc URL	https://hdl.handle.net/2115/95898
Rights	This is the peer-reviewed but unedited manuscript version of the following article:Shinya Morita, Yuji Nakamaru, Atsushi Fukuda, Keishi Fujiwara, Masanobu Suzuki, Kimiko Hoshino, Aya Honma, Akira Nakazono, Akihiro Homma; Neutrophil Extracellular Trap Formation and Deoxyribonuclease I Activity in Patients with Otitis Media with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Int Arch Allergy Immunol 7 August 2024; 185 (8): 810-819. https://doi.org/10.1159/000537927 . The final, published version is available at http://karger.com/?doi=10.1159/000537927 .
Type	journal article
File Information	HUSCAP_DNaseI-International Archives of Allergy and Immunology-manuscript-clean-revised2.pdf



1 **Neutrophil extracellular trap formation and deoxyribonuclease I activity in**
2 **patients with otitis media with antineutrophil cytoplasmic antibody-**
3 **associated vasculitis**

4
5
6 Shinya Morita, Yuji Nakamaru, Atsushi Fukuda, Keishi Fujiwara, Masa
7 nobu Suzuki, Kimiko Hoshino, Aya Honma, Akira Nakazono, Akihiro
8 Homma

9
10 Affiliations:

11 Department of Otolaryngology - Head and Neck Surgery, Faculty of Me
12 dicine and Graduate School of Medicine, Hokkaido University, Sapporo,
13 Japan

14
15 Short title:

16 Neutrophil extracellular trap and Deoxyribonuclease I in Otitis Media

17
18 Corresponding author:

19 Shinya Morita

20 E-mail address: shinyamorita@huhp.hokudai.ac.jp

22 Key Words:

23 neutrophil extracellular traps; myeloperoxidase-deoxyribonucleic acid

24 complex; citrullinated-histone H3-deoxyribonucleic acid complex;

25 deoxyribonuclease I; otitis media with antineutrophil cytoplasmic antibody-

26 associated vasculitis

27

Abstract

Introduction: No previous studies have evaluated the levels of neutrophil extracellular trap (NET) remnants or the importance of deoxyribonuclease (DNase) I activity based on the disease activity of otitis media with antineutrophil cytoplasmic antibody-associated vasculitis (OMAAV). The aim of this study was to explore the formation of NETs in the middle ear of patients with OMAAV during the onset and remission phases of the disease, with a particular focus on the relationships between the quantifiable levels of NET remnants and DNase I activity.

Methods: OMAAV patients were eligible for inclusion. Patients with otitis media with effusion (OME) were examined as controls. The levels of cell-free deoxyribonucleic acid (DNA), citrullinated-histone H3 (cit-H3)-DNA complex and myeloperoxidase (MPO)-DNA complex were quantified using an enzyme-linked immunosorbent assay. DNase I activity was measured using a fluorometric method.

Results: The quantifiable levels of cell-free DNA, cit-H3-DNA complex and MPO-DNA complex in the middle ear lavage of patients with OMAAV at onset were significantly higher than those in patients with OMAAV at remission and in patients with OME. DNase I activity in the patients with OMAAV at onset was significantly lower than those in patients with OMAAV at remission and OME, and was negatively correlated with the level of MPO-DNA complex.

Conclusions: This study suggests that NET remnants and DNase I activity may be potentially useful biomarkers for the diagnosis and disease activity of

52 OMAAV.

53

Introduction

Otitis media with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (OMAAV) is a relatively rare disease, which occasionally progresses to complete deafness and the systemic form of ANCA-associated vasculitis (AAV) [1]. AAV is comprised of granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA), which commonly involves various organs and is a life-threatening disorder [2]. In 2004, Brinkmann et al. demonstrated that neutrophil extracellular traps (NETs) were released as a result of neutrophil extracellular trap cell death distinct from apoptosis and necrosis [3]. NETs are composed of extracellular deoxyribonucleic acid (DNA) fibers and histones decorated with various enzymes. Although the source of extracellular DNA contained in NETs is less unambiguous, its fractions have been considered to be of either mitochondrial or nuclear in origin [4]. Several pathways of NET formation have been recently described, and NET extrusion does not necessarily result in cellular lysis [4, 5]. NETs lead to the formation of a physical net in which pathogens are entrapped and killed by elastase, defensin, and reactive oxygen species [3-7]. Despite their beneficial effects in host defense, the excessive formation of NETs induces vessel wall inflammation, thrombosis, and pathogenic ANCA [8, 9]. Several studies have suggested that the vicious cycle of NETs-ANCA induction could be critical to the pathogenesis of OMAAV [8-10].

Although the formation and degradation of NETs are regulated in a strict manner, a failure in regulation leads to unfavorable consequences. It has

been generally recognized that members of the deoxyribonuclease (DNase) families play vital roles in the degradation of extracellular DNA, including NETs, by targeting and cleaving DNA sequences [11]. The DNase I and DNase II families are the major DNase families, and multiple enzymes in each family play diverse roles in the development of various diseases [12]. The DNase I family consists of a number of distinct DNases, including DNase I, DNase X, DNase γ , DNAS1L2 and DNAS1L3 [11-13]. DNase I, a major nuclease present in the blood and other body fluids, is the enzyme that is secreted outside of cells and cleaves extracellular DNA [11, 14]. The physiological increases and decreases in extracellular DNA are regulated to some extent by DNase I [15], which may be crucial for the prevention of autoimmune reactions [16]. Thus, reduced levels of DNase I lead to impaired fragmentation and elimination of chromatin, resulting in the accumulation of chromatin fragments in complex with chromatin-specific autoantibodies [11, 12]. Previous studies have reported that DNase I activity is related to the occurrence of systemic autoimmune diseases including MPA and systemic lupus erythematosus (SLE), suggesting that serum DNase I activity might be an indicator of the ongoing NET formation and a useful biomarker for the diagnosis and disease activity of autoimmune diseases [17, 18].

Cell-free DNA, citrullinated-histone H3 (cit-H3)-DNA complex, and myeloperoxidase (MPO)-DNA complex, as a surrogate for the formation of NETs, may be potentially useful as markers for assessing the development and prognosis of autoimmune diseases [8, 17, 19-22]. A recent study

indicated high levels of these NET remnants in patients with OMAAV at disease onset [10]. However, no previous studies evaluated the levels of NET remnants or the importance of DNase I activity based on OMAAV disease activity. Long-lasting exposure to NETs that are digested poorly due to low DNase I activity may result in severe, life-threatening complications [16]. Therefore, the aim of this study was to explore the formation of NETs in the middle ear of patients with OMAAV during the onset and remission phases of the disease, with a particular focus on the relationships between the quantifiable levels of NET remnants and DNase I activity.

Materials and methods

Ethics

This prospective study included patients diagnosed with OMAAV in the Department of Otolaryngology, Head and Neck Surgery, Hokkaido University Hospital between April 2021 and March 2023. All patients were instructed on the potential risks and benefits of the management program, and written informed consent to participate in the study and for the use of their samples and clinical data was obtained after a full explanation. This research adhered to the tenets of the Declaration of Helsinki and was approved by our Institutional Review Board (No. 021-0230).

Patients and controls

OMAAV patients were eligible for inclusion in this analysis. OMAAV was diagnosed using the criteria proposed by the OMAAV study group of the Japan Otological Society as follows: 1) intractable otitis media with effusion or granulation, which was resistant to antibiotics and insertion of tympanic ventilation tubes, accompanied by progressive hearing loss; 2) at least one of the following four findings: (a) diagnosis of GPA, MPA and EGPA before the occurrence of ear symptoms; (b) positivity for serum MPO- or PR3-ANCA; (c) histopathologically consistent with AAV; and (d) at least one accompanying AAV-related symptom involving organs other than the ear (eye, nose, pharynx/larynx, lung, kidney, facial palsy, hypertrophic pachymeningitis, mononeuropathy and others); and 3) exclusion of other types of intractable otitis media such as bacterial otitis media, cholesterol granuloma,

cholesteatoma, malignant osteomyelitis, tuberculosis, neoplasms and eosinophilic otitis media, as well as exclusion of other autoimmune diseases and vasculitis other than AAV, such as Cogan's syndrome and polyarteritis nodosa among others [1].

Patients with otitis media with effusion (OME) were examined as controls. OME was defined as the presence of fluid in the middle ear without signs or symptoms of acute ear infection based on the clinical practice guidelines on OME published by the American Academy of Otolaryngology Head and Neck Surgery Foundation [23].

The exclusion criteria for subjects and controls were as follows: 1) fluid samples of less than 0.1 ml that cannot provide a quantifiable level of NET remnants; 2) a history of definitive ear disease such as familial hearing loss, chronic noise exposure, ototoxic drug intake, head trauma, radiation therapy, acoustic neuroma or inner ear malformation; 3) a history of cancer, diabetes, deep vein thrombosis, acute coronary syndrome, ischemic stroke or other systemic autoimmune diseases such as Cogan's syndrome, SLE, rheumatoid arthritis, IgG4-related disease, sarcoidosis or aortitis syndrome, in which NETs may be involved [7, 18, 19, 21, 24, 25]; 4) pregnancy; and 5) less than 20 years of age.

Treatment Procedure

The treatment protocol was adjusted based on the severity of disease, age, comorbidities, patient wishes and/or the attending physician's discretion in each case. Patients with OMAAV were essentially treated with intravenous

160 methylprednisolone pulse therapy (500-1000 mg/body/day) for 3 days
161 followed by high-dose oral prednisolone (1 mg/kg/day) for 4 or more weeks at
162 active-stage, which was then tapered gradually and maintained (5-10
163 mg/body/day) while serum ANCA titer and C-reactive protein levels were
164 monitored. An immunosuppressant, such as cyclophosphamide, rituximab,
165 methotrexate or azathioprine, was added to the steroid therapy.

167 *Evaluation of the disease activity*

168 The disease activity of vasculitis was measured using the Birmingham
169 Vasculitis Activity Score (BVAS) version 3.0, which was previously validated
170 and has been generally used for clinical trials for vasculitis [26]. The BVAS
171 form is divided into 9 organ-based systems, with each section including
172 symptoms that are typical of that particular organ involvement in systemic
173 vasculitis. The scores range from 0 to 63, and higher scores indicate more
174 active disease. Remission of OMAAV was defined as a state in which the
175 BVAS was 0 (or ≤ 1 , if all items were persistent) and the maintenance dose of
176 oral prednisolone was ≤ 10 mg/body/day [26].

178 *Sample collection*

179 The middle ear lavage samples were obtained at onset (initial
180 presentation) and remission of disease. Tympanic membrane anesthesia
181 using iontophoresis was applied to the external auditory canal with 4%
182 lidocaine (AstraZeneca Co., Ltd., London, UK). The samples were aspirated
183 from the middle ear through the anterior-inferior portion of the tympanic

membrane using a 1-ml tuberculin syringe with a 24- or 26-gauge needle under a microscope by lavaging the middle ear cavity with a 0.3-ml saline bolus. In cases of OMAAV with tympanic membrane perforation or tympanic ventilation tube insertion during remission, the middle ear lavage samples were collected through these routes in similar manner. The supernatants were centrifuged at 1500 rpm for 5 minutes and stored at -80 °C until analysis.

Blood was collected into serum separator tubes containing clot activator and serum separator gel by a trained hospital phlebotomist at disease onset (initial presentation) and remission. After completion of biochemical testing ordered by the clinician, the remaining serum was released to the research laboratory. Serum samples were immediately divided into small aliquots and stored at -80°C until analysis.

Immunofluorescent staining

For histological analysis, each middle ear lavage sample was immediately smeared on a glass slide. To identify the formation of NETs, DNA and cit-H3 as the main components and MPO as neutrophil-specific granules were visualized simultaneously by immunofluorescence, as previously described [17, 27]. The samples on the glass slides were fixed with 4% paraformaldehyde for 30 min, washed with phosphate-buffered saline (PBS), and then incubated for 60 min with a mouse anti-histone H3 (citrulline R2+R8+R17) antibody (Abcam, ab5103) and a mouse anti-human MPO antibody (4A4; Bio-Rad Laboratories, Tokyo, Japan) as the primary

antibody. After washing in PBS, each primary antibody was visualized using secondary antibodies coupled to Alexa Fluor 555 goat anti-rabbit IgG (Invitrogen, A27039) and Alexa Fluor 488 goat anti-mouse IgG (Invitrogen, A11001). After incubation for 60 min with the secondary antibodies, the specimens were washed with PBS, and the DNA was stained with 4', 6-diamidino-2-phenylindole (DAPI; Invitrogen, P36962) in PBS for 5 min. All procedures were performed at room temperature. The specimens were analyzed using a confocal laser-scanning microscope (LSM 710; ZEISS, Jena, Germany). This analysis considered string- or web-like extracellular DNA and cit-H3 extending from the cell body colocalized with MPO to be NETs-positive cells. Samples were considered negative for the presence of NETs if no cells harboring NETs were identified in 300 neutrophils by immunostaining.

Evaluation of the cell-free DNA level

The cell-free DNA level in the middle ear lavage was determined by enzyme-linked immunosorbent assay (ELISA) using Cell Death Detection ELISA PLUS (Roche, Cat. No: 1177442500) according to the manufacturer's protocol [8, 10, 20-22]. The determination was based on quantitative sandwich ELISA using anti-DNA antibody and anti-histones antibody, specifically binding mono- and oligonucleosomes derived from the nuclei of eukaryotic cells. The optical absorbance was measured at 405 nm using an ELISA reader (Bio-Rad 680; Bio-Rad Laboratories, Tokyo, Japan).

Evaluation of the cit-H3-DNA complex level

The cit-H3-DNA complex level in the middle ear lavage was quantified using ELISA, as previously described [8, 10, 20-22]. An anti-histone H3 (citrulline R2+R8+R17) antibody (Abcam, ab5103) was coated on 96-well microtiter plates, with 1% bovine serum albumin used for blocking. The fluid sample, together with a peroxidase-labeled anti-DNA monoclonal antibody (Cell Death Detection ELISA kit; Roche, Cat. No.: 11774425001), was then added. The optical absorbance was measured at 405 nm using an ELISA reader (Bio-Rad 680; Bio-Rad Laboratories, Tokyo, Japan).

Evaluation of the MPO-DNA complex level

The MPO-DNA complex level in the middle ear lavage was quantified using ELISA, as previously described [8, 10, 17, 27]. A mouse anti-human MPO antibody (4A4; Bio-Rad Laboratories, Tokyo, Japan) was coated on 96-well microtiter plates. After blocking with 1% bovine serum albumin, the fluid sample was then added together with a peroxidase-labeled anti-DNA monoclonal antibody (Cell Death Detection ELISA kit; Roche, Cat. No.: 11774425001). After incubation, the peroxidase substrate was added according to the manufacturer's instructions. The optical absorbance was measured at 405 nm using an ELISA reader (Bio-Rad 680; Bio-Rad Laboratories, Tokyo, Japan).

Measurement of DNase I activity

DNase I activity in serum was measured using a DNase I Activity Assay

Kit (Abcam, ab234056) according to the manufacturer's protocol. Samples, a positive control, and a background control were added together with DNA probe to each well. Enzyme activity was detected upon cleavage of a DNA probe, which yields a fluorescent DNA product measured at Ex/Em = 651/681 nm in kinetic mode every 30 seconds for 90 minutes at 37°C, using a SpectraMax Plus microplate spectrophotometer (Molecular Devices, Sunnyvale, CA, USA).

Statistical analysis

Statistical analyses were performed using GraphPad Prism software (version 6.0; GraphPad Software Inc.; La Jolla, CA, U.S.A.). Statistical differences were analyzed using the Wilcoxon matched-pairs signed-ranks test, Mann-Whitney U-test for two independent groups and Kruskal-Wallis test for three or more independent groups, with a *p* value of less than 0.05 considered statistically significant. Differences in quantitative data were analyzed using one-way ANOVA among more than three groups, followed by a post-hoc Steel-Dwass test. Potential associations between the levels of NET remnants and DNase I activity for patients with OMAAV were determined using Spearman's correlation analysis.

Results

Clinical profiles of patients and controls

Characteristics of the patients with OMAAV and controls are summarized in the Table. The patient group comprised 37 subjects, consisting of 10 males and 27 females, ranging in age from 48 to 84 years (median, 67 years). Nine patients were diagnosed with GPA, 8 with MPA, 11 with EGPA and 9 patients with localized forms of OMAAV. Twenty-three patients were MPO-ANCA positive and 5 patients were PR3-ANCA positive, whereas 9 patients were ANCA negative at the initial time of sampling. As a systemic treatment, 32 patients were treated with steroid pulse therapy followed by high-dose prednisolone combined with immunosuppressive agents (cyclophosphamide, rituximab, methotrexate or azathioprine), 3 patients with steroid pulse therapy followed by high-dose prednisolone, and 2 patients with high-dose prednisolone monotherapy. The dose of oral prednisolone was tapered and maintained ≤ 10 mg/body/day while the BVAS was ≤ 1 , and serum ANCA titer and C-reactive protein levels were normalized. The resolution of middle ear effusion or granulation was confirmed using otoscopic examination or CT scanning during remission of disease.

The control group comprised 37 subjects, consisting of 18 males and 19 females, ranging in age from 44 to 83 years (median, 67 years). There were no differences in background characteristics, such as age or gender distribution, between the patient and control groups.

Presence of NETs in the middle ear lavage samples for patients and controls

Hematoxylin-eosin staining detected high numbers of neutrophils in the middle ear lavage samples in patients with OMAAV at onset (Fig. 1a), while lower numbers of neutrophils were detected in patients with OME (Fig. 1b). Triple staining with DNA, cit-H3, and neutrophil-specific proteins was then performed using the middle ear lavage samples, and NET formation was identified in all patients with OMAAV at onset (Fig. 2). Meanwhile, no NET formation was observed in the samples from patients with OME (Fig. 2).

The levels of cell-free DNA, cit-H3-DNA complex and MPO-DNA complex in patients with OMAAV at onset and remission

Fig. 3a-f shows the ELISA levels of NET remnants in the patients with OMAAV and OME. The mean quantifiable levels of cell-free DNA, cit-H3-DNA complex and MPO-DNA complex expressed as arbitrary units (a.u.) were 14.2 a.u. (ranging from 0.01 to 48.2 a.u.), 12.6 a.u. (ranging from 0.01 to 41.9 a.u.), and 11.2 a.u. (ranging from 0.11 to 32.6 a.u.) in the patients with OMAAV at onset, 1.33 a.u. (ranging from 0.01 to 3.77 a.u.), 1.11 a.u. (ranging from 0.01 to 3.87 a.u.), and 0.89 a.u. (ranging from 0.02 to 2.93 a.u.) in the patients with OMAAV at remission, and 0.73 a.u. (ranging from 0.02 to 2.93 a.u.), 0.73 a.u. (ranging from 0.01 to 3.50 a.u.), and 0.73 a.u. (ranging from 0.01 to 3.50 a.u.) in the patients with OME, respectively. Patients with OMAAV at onset showed significantly higher levels of cell-free DNA ($p<0.001$ and $p<0.001$, respectively), cit-H3-DNA complex ($p<0.001$ and $p<0.001$, respectively) and MPO-DNA complex ($p<0.001$ and $p<0.001$, respectively)

324 compared with the patients with OMAAV at remission and those with OME,
325 respectively. Meanwhile, there was no significant difference in the levels of
326 NET remnants between patients with OMAAV at remission and those with
327 OME.

328 *DNase I activity in patients with OMAAV*

330 Fig. 4a and 4b shows the serum DNase I activity in the patients with
331 OMAAV and OME. The mean quantifiable serum DNase I level was 160
332 nU/ml (ranging from 53 to 432 nU/ml) in the patients with OMAAV at onset,
333 600 nU/ml (ranging from 200 to 1173 nU/ml) in the patients with OMAAV at
334 remission, and 651 nU/ml (ranging from 344 to 1026 nU/ml) in the patients
335 with OME, respectively. The DNase I activity in the patients with OMAAV at
336 onset was significantly lower in comparison with that in the patients with
337 OMAAV at remission ($p<0.001$) and OME ($p<0.001$), respectively. Meanwhile,
338 no significant difference in the DNase I activity was found between patients
339 with OMAAV at remission and those with OME. It is important to stress that
340 DNase I activity in the patients with OMAAV at remission reached an
341 equivalent level to that in patients with OME.

342 *The correlation between DNase I activity and cell-free DNA, cit-H3-DNA 343 complex or MPO-DNA complex*

345 The correlations between DNase I activity and each NET remnant were
346 examined (Fig. 5a-c). DNase I activity was negatively correlated with MPO-
347 DNA complex ($r=-0.40$, $p=0.015$), while there was no significant correlation

348 between DNase I activity and cell-free DNA or cit-H3-DNA complex.

349

350

Discussion

The excessive formation of NETs has been suggested to be involved in the pathogenesis of OMAAV [10, 28, 29]. Novel methods for the evaluation of NETs are essential to providing a definite diagnosis as well as to predicting the activity and severity of OMAAV [28]. To date, immunofluorescent staining has been widely used to visualize and directly evaluate the formation of NETs [30]. The presence of NETs is defined by the identification of web-like extracellular DNA colocalized with citrullinated histones and neutrophil-derived proteins extending from neutrophils [17, 26]. This study demonstrated that NET formation in middle ear lavage of patients with OMAAV at onset could be identified by immunofluorescent staining. It has been generally recognized that the accumulation of NETs in localized regions, such as the skin, kidneys, lungs and peripheral nerves, is a characteristic of AAV and results in tissue damage [8, 9]. The deposition of NETs in the middle ear of patients with OMAAV may play a central role in disease pathogenesis through complement activation, neutrophilic infiltration and the release of destructive enzymes which, in turn, lead to damage to the stria vascularis and hair cells in the cochlea. However, the lack of objectivity and quantitativity remain critical methodological drawbacks to immunofluorescent staining [30].

In the case of fluid samples, the soluble NET remnants could be quantified using ELISA. This study demonstrated that the quantifiable levels of cell-free DNA, cit-H3-DNA complex and MPO-DNA complex were higher in the middle ear lavage of patients with OMAAV at onset in

comparison with those in patients with OME. In particular, even ANCA-negative cases indicated high quantifiable levels of cell-free DNA, cit-H3-DNA complex and MPO-DNA complex. These findings suggest that NET remnants may be useful as a biomarker for the diagnosis of OMAAV. However, many researchers have noted that the presence of soluble NET remnants is not a direct indication of NET formation [4, 30]. In particular, cell-free DNA might be derived from dead cells, such as apoptosis and necrosis [30], and be attributed to a phenomenon known to occur during infection and delays in clearance by phagocytosis [4]. Cit-H3-DNA complex might also be generated by cells other than neutrophils, such as macrophages, mast cells and eosinophils [31-34].

It is noteworthy that no NET formation was identified by immunofluorescent staining in the middle ear lavage of patients with OMAAV at remission, and the quantifiable ELISA levels of cell-free DNA, cit-H3-DNA complex and MPO-DNA complex were equivalent to those in patients with OME. These findings suggest that the formation and accumulation of NETs may be useful as an indicator of disease activity in patients with OMAAV. The level of NET remnants could allow early assessment for deciding the appropriate dose of medication as maintenance immunosuppressive therapy for patients with OMAAV during the remission stage of the disease. In addition, such assessment could allow more aggressive treatments to target OMAAV with a high level of NET remnants, particularly in relation to subjects with a poor prognosis.

The clearance of NETs also has a pivotal role in the induction of

autoimmune disease [35]. Previous studies have shown that the decreased clearance of NETs is correlated with DNase I activity, suggesting DNase I is responsible for NETs degradation [17, 26, 35]. Low DNase I activity could lead to the persistence of NETs and an immunological imbalance [17, 26, 35]. DNase I is inhibited by complement over-activation as well as excessive deposition of the complement protein, C1q, which results in an inability to degrade NETs [37]. This study showed that DNase I activity in the patients with OMAAV at onset was significantly lower than that in the patients with OME, which is consistent with the previous published findings regarding SLE and MPA [17, 18]. Additionally, DNase I activity was negatively correlated with the levels of MPO-DNA complex. The accumulation of NETs due to disordered DNase I activity may induce ANCA production and activate complement [8, 9, 12]. ANCA stimulates neutrophils and induces the formation of NETs, the production of oxygen radicals and proinflammatory cytokines, which then exaggerate the autoimmune response [8, 9]. Thus, DNase I may play a key role in the vicious cycle of NETs-ANCA induction involved in the pathogenesis of OMAAV. It is noteworthy that DNase I activity in the patients with OMAAV at remission improved to the equivalent level as that in the patients with OME. Patients with OMAAV undergoing steroid and immunosuppressant therapy could normalize the ability to degrade NETs, suggesting that DNase I activity may be useful as an indicator of disease activity.

Limitations

This study had several limitations. The results of the analyses might have been affected by the small number of samples, as well as by the detection and quantification methods employed for NETs and DNase I activity, and the absence of experimental evidence in support of cell death. To date, various methods and markers have been utilized to demonstrate the formation of NETs in vitro and in vivo [30]. It should be noted that the soluble NET remnants quantified using ELISA, such as cell-free DNA, cit-H3-DNA complex, and MPO-DNA complex were based on an unspecific bioassay for NET formation, making it challenging to distinguish between NET formation and other forms of cell death with necrotic morphotype [4, 30]. Methods for the quantification of DNase I activity, such as colorimetry, precipitation, fluorometry, and viscometry, are limited by technical and biological factors. The technical factors include sample processing, choice of collection tube, and hemolysis [38]. The biological factors that could affect DNase I activity are physical activity, circadian rhythm, and hormones [15]. Additionally, it remains unclear how other enzymes in the DNase I family, such as DNase X, DNase γ , DNAS1L2 and DNAS1L3, affect the degradation of NETs [11-13]. The relationship between NET accumulation, DNase I activity, and/or the activity and severity of OMAAV is not fully elucidated. Therefore, further studies are required to understand the role of NETs and DNases I in the pathogenesis of OMAAV.

Conclusion

This analysis demonstrated that immunofluorescent staining could be used to identify NET formation in the middle ear lavage of patients with OMAAV at onset and the quantifiable ELISA levels of NET remnants, such as cell-free DNA, cit-H3-DNA complex and MPO-DNA complex, were significantly higher compared with those in patients with OMAAV at remission and those with OME. Furthermore, DNase I activity in the patients with OMAAV at onset was significantly lower than those in the patients with OMAAV at remission and OME, and was negatively correlated with the level of MPO-DNA complex. It should be noted that the levels of NET remnants and DNase I activity in the patients with OMAAV after remission induction therapy improved to the equivalent levels as those in the patients with OME. These findings would suggest that NET remnants and DNase I activity may be potentially useful as biomarkers for the diagnosis and disease activity of OMAAV.

Ethics statement

This research adhered to the tenets of the Declaration of Helsinki. The protocol was reviewed and approved by the Ethics Committee of Hokkaido University Hospital with approval No. 021-0230. All patients were instructed on the potential risks and benefits of the management program, and written informed consent to participate in the study and for the use of their samples and clinical data was obtained after a full explanation.

Acknowledgement

The authors would like to thank the OMAAV study group of the Japan Otological Society for supporting their work.

Conflicts of interest

We have no conflicts of interest to declare.

Funding sources

This study received financial support from Japan Society for the Promotion of Science, KAKENHI (Grant Number 20K09744).

Author contributions

Shinya Morita designed the study, performed the experiments, and drafted the manuscript. Yuji Nakamaru designed the study and edited the manuscript. Atsushi Fukuda, Keishi Fujiwara, Masanobu Suzuki, Kimiko Hoshino, Aya Honma and Akira Nakazono provided scientific advice, clinical

485 samples and data. Akihiro Homma supervised the research and revised the
486 final manuscript.

487
488 **Data availability statement**

489 All data generated or analysed during this study are included in this
490 article. Further enquiries can be directed to the corresponding author.

References

1. Harabuchi Y, Kishibe K, Tateyama K, Morita Y, Yoshida N, Kunitomo Y, et al. Clinical Features and Treatment Outcomes of Otitis Media With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (OMAAV): A Retrospective Analysis of 235 Patients From a Nationwide Survey in Japan. *Mod Rheumatol*. 2017;27(1):87-94.
2. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. *Arthritis Rheum*. 2013;65(1):1-11.
3. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, et al. Neutrophil Extracellular Traps Kill Bacteria. *Science*. 2004;303(5663):1532-5.
4. Boeltz S, Amini P, Anders HJ, Andrade F, Bilyy R, Chatfield S, et al. To NET or not to NET: current opinions and state of the science regarding the formation of neutrophil extracellular traps. *Cell Death Differ*. 2019;26(3):395-408.
5. Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. *Cell Death Differ*. 2018;25(3):486-541.

6. Urban CF, Ermert D, Schmid M, Abu-Abed U, Goosmann C, Nacken W, et al. Neutrophil Extracellular Traps Contain Calprotectin, a Cytosolic Protein Complex Involved in Host Defense against *Candida Albicans*. *PLoS Pathog.* 2009;5(10):e1000639.
7. Garcia-Romo GS, Caielli S, Vega B, Connolly J, Allantaz F, Xu Z, et al. Netting Neutrophils are Major Inducers of Type I IFN Production in Pediatric Systemic Lupus Erythematosus. *Sci Transl Med.* 2011;3(73):73ra20.
8. Kessenbrock K, Krumbholz M, Schönermarck U, Back W, Gross WL, Werb Z, et al. Netting Neutrophils in Autoimmune Small-Vessel Vasculitis. *Nat Med.* 2009;15(6):623-5.
9. Zawrotniak M, Rapala-Kozik M. Neutrophil Extracellular Traps (NETs)-Formation and Implications. *Acta Biochim Pol.* 2013;60(3):277-84.
10. Morita S, Nakamaru Y, Nakazawa D, Suzuki M, Hoshino K, Fukuda A, et al. The Diagnostic and Clinical Utility of the Myeloperoxidase-DNA Complex as a Biomarker in Otitis Media With Antineutrophil Cytoplasmic Antibody-associated Vasculitis. *Otol Neurotol.* 2019;40(2):e99-e106.
11. Mori G, Delfino D, Pibiri P, Rivetti C, Percudani R. Origin and Significance of the Human DNase Repertoire. *Sci Rep.* 2022;12(1):10364.

12. Keyel PA. DNases in Health and Disease. *Dev Biol.* 2017;429(1):1-11.
13. Shiokawa D, Tanuma S. Characterization of Human DNase I Family Endonucleases and Activation of DNase Gamma during Apoptosis. *Biochemistry.* 2001;40(1):143-52.
14. Napirei M, Ricken A, Eulitz D, Knoop H, Mannherz HG. Expression Pattern of the Deoxyribonuclease 1 gene: Lessons from the Dnase1 Knockout Mouse. *Biochem J.* 2004;380 (Pt 3):929-37.
15. Avall-Lundqvist E, Economidou-Karaoglou A, Sjövall K, Lans M, Taper HS, Roberfroid M, et al. Serum Alkaline DNase Activity in Normal or Nonhospitalised Individuals. *Clin Chim Acta.* 1989;185(1):35-43.
16. Lauková L, Konečná B, Janovičová L, Vlková B, Celec P. Deoxyribonucleases and Their Applications in Biomedicine. *Biomolecules.* 2020;10(7):1036.
17. Nakazawa D, Shida H, Tomaru U, Yoshida M, Nishio S, Atsumi T, et al. Enhanced Formation and Disordered Regulation of NETs in Myeloperoxidase-ANCA-associated Microscopic Polyangiitis. *J Am Soc Nephrol.* 2014;25(5):990-7.

18. Hakkim A, Furnrohr BG, Amann K, Laube B, Abed UA, Brinkmann V, et al. Impairment of Neutrophil Extracellular Trap Degradation is Associated With Lupus Nephritis. *Proc Natl Acad Sci USA*. 2010;107(21):9813-8.
19. Leffler J, Gullstrand B, Jönsen A, Nilsson JA, Martin M, Blom AM, et al. Degradation of Neutrophil Extracellular Traps Co-varies with Disease Activity in Patients with Systemic Lupus Erythematosus. *Arthritis Res Ther*. 2013;15(4):R84.
20. Söderberg D, Kurz T, Motamedi A, Hellmark T, Eriksson P, Segelmark M. Increased Levels of Neutrophil Extracellular Trap Remnants in the Circulation of Patients with Small Vessel Vasculitis, But an Inverse Correlation to Anti-neutrophil Cytoplasmic Antibodies during Remission. *Rheumatology (Oxford)*. 2015;54(11):2085-94.
21. Arai Y, Yamashita K, Mizugishi K, Watanabe T, Sakamoto S, Kitano T, et al. Serum Neutrophil Extracellular Trap Levels Predict Thrombotic Microangiopathy after Allogeneic Stem Cell Transplantation. *Biol Blood Marrow Transplant*. 2013;19(12):1683-9.
22. Wang H, Sha LL, Ma TT, Zhang LX, Chen M, Zhao MH. Circulating Level of Neutrophil Extracellular Traps is Not a Useful Biomarker for Assessing Disease Activity in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. *PLoS One*. 2016;11(2):e0148197.

588

589 23. Rosenfeld RM, Shin JJ, Schwartz SR, Coggins R, Gagnon L, Hackell JM,
590 et al. Clinical Practice Guideline: Otitis Media With Effusion Executive
591 Summary (update). *Otolaryngol Head Neck Surg.* 2016;154(2):201-14.

592

593 24. D'Antonio M, Weghorn D, D'Antonio-Chronowska A, Coulet F, Olson KM,
594 DeBoever C, et al. Identifying DNase I Hypersensitive Sites as Driver Distal
595 Regulatory Elements in Breast Cancer. *Nat Commun.* 2017;8(1):436.

596

597 25. Hawes MC, Wen F, Elquza E. Extracellular DNA: a Bridge to Cancer.
598 *Cancer Res.* 2015;75(20):4260-4.

599

600 26. Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, et al.
601 Modification and validation of the Birmingham Vasculitis Activity Score
602 (version 3). *Ann Rheum Dis.* 2009;68(12):1827-32.

603

604 27. Nakazawa D, Tomaru U, Suzuki A, Masuda S, Hasegawa R, Kobayashi
605 T, et al. Abnormal Conformation and Impaired Degradation of
606 Propylthiouracil-induced Neutrophil Extracellular Traps: Implications of
607 Disordered Neutrophil Extracellular Traps in a Rat Model of
608 Myeloperoxidase Antineutrophil Cytoplasmic Antibody-Associated
609 Vasculitis. *Arthritis Rheum.* 2012;64(11):3779-87.

610

611 28. Morita S, Nakamaru Y, Fukuda A, Fujiwara K, Suzuki M, Hoshino K, et

al. The Quantification of Extracellular Trap Cell Death-Derived Products as Diagnostic Biomarkers for Otitis Media With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis and Eosinophilic Otitis Media. *Otol Neurotol.* 2022;43(3):e337-43.

29. Morita S, Nakamaru Y, Nakazawa D, Hattanda F, Shida H, Kusunoki Y, et al. Elevated Level of Myeloperoxidase-Deoxyribonucleic Acid Complex in the Middle Ear Fluid Obtained From Patients With Otitis Media Associated With Antineutrophil Cytoplasmic Antibody-associated Vasculitis. *Otol Neurotol.* 2018;39(4):e257-62.

30. Masuda S, Nakazawa D, Shida H, Miyoshi A, Kusunoki Y, Tomaru U, et al. NETosis markers: Quest for Specific, Objective, and Quantitative Markers. *Clin Chim Acta.* 2016;459:89-93.

31. Goldmann O, Medina E. The Expanding World of Extracellular Traps: Not Only Neutrophils But Much More. *Front Immunol.* 2012;3:420.

32. Mohanan S, Horibata S, McElwee JL, Dannenberg AJ, Coonrod SA. Identification of Macrophage Extracellular Trap-Like Structures in Mammary Gland Adipose Tissue: A Preliminary Study. *Front Immunol.* 2013;4:67.

33. Lin AM, Rubin CJ, Khandpur R, Wang JY, Riblett M, Yalavarthi S, et al.

Mast Cells and Neutrophils Release IL-17 through Extracellular Trap Formation in Psoriasis. *J Immunol.* 2011;187(1):490-500.

34. Simon D, Hoesli S, Roth N, Staedler S, Yousefi S, Simon HU. Eosinophil Extracellular DNA Traps in Skin Diseases. *J Allergy Clin Immunol.* 2011;127(1):194-9.

35. Angeletti A, Volpi S, Bruschi M, Lugani F, Vaglio A, Prunotto M, et al. Neutrophil Extracellular Traps-DNase Balance and Autoimmunity. *Cells.* 2021;10(10):2667.

36. Malíčková K, Duricová D, Bortlík M, Hrušková Z, Svobodová B, Machková N, et al. Impaired Deoxyribonuclease I Activity in Patients With Inflammatory Bowel Diseases. *Autoimmune Dis.* 2011;2011:945861.

37. Leffler J, Martin M, Gullstrand B, Tyden H, Lood C, Truedsson L, et al. Neutrophil Extracellular Traps That are Not Degraded in Systemic Lupus Erythematosus Activate Complement Exacerbating the Disease. *J Immunol.* 2012;188(7):3522-31.

38. Barra GB, Santa Rita TH, de Almeida Vasques J, Chianca CF, Nery LF, Santana Soares Costa S. EDTA-mediated inhibition of DNases protects circulating cell-free DNA from ex vivo degradation in blood samples. *Clin Biochem.* 2015;48(15):976-81.

Figure legends

Fig. 1. Hematoxylin-eosin staining of the middle ear lavage samples in patients with OMAAV (a) and OME (b).

OMAAV; otitis media with antineutrophil cytoplasmic antibody-associated vasculitis, OME; otitis media with effusion

Fig. 2. Immunofluorescent staining by DNA, cit-H3, and MPO of the middle ear lavage samples in patients with OMAAV and OME.

DNA; deoxyribonucleic acid, cit-H3; citrullinated-histone H3, MPO; myeloperoxidase, OMAAV; otitis media with antineutrophil cytoplasmic antibody-associated vasculitis, OME; otitis media with effusion

Fig. 3. The levels of cell-free DNA (a), cit-H3-DNA complex (b) and MPO-DNA complex (c) in the patients with OMAAV at onset and those with OME. The levels of cell-free DNA (d), cit-H3-DNA complex (e) and MPO-DNA complex (f) in the patients with OMAAV at onset and remission.

DNA; deoxyribonucleic acid, cit-H3; citrullinated-histone H3, MPO; myeloperoxidase, OMAAV; otitis media with antineutrophil cytoplasmic antibody-associated vasculitis, OME; otitis media with effusion

Fig. 4. The serum DNase I activity in the patients with OMAAV and OME (a). The serum DNase I activity in the patients with OMAAV at onset and remission (b).

684 DNase I; deoxyribonuclease I, OMAAV; otitis media with antineutrophil
685 cytoplasmic antibody-associated vasculitis, OME; otitis media with effusion
686
687 Fig. 5. The correlations between DNase I activity and cell-free DNA (a), cit-
688 H3-DNA complex (b) or MPO-DNA complex (c).
689 DNase I; deoxyribonuclease I, DNA; deoxyribonucleic acid, cit-H3;
690 citrullinated-histone H3, MPO; myeloperoxidase


Table. Characteristics of patients with otitis media with antineutrophil cytoplasmic antibody-associated vasculitis and controls

Parameter	patients	controls	<i>p</i> values
Numbers (n)	37	37	
Age (years)			0.71
range	48 - 84	44 - 83	
median	67	67	
Gender (n)			0.22
Female	27	19	
Male	10	18	
AAV classification (n)			
GPA	9		
MPA	8		
EGPA	11		
Localized	9		
ANCA status (n)			
MPO-ANCA (+), PR3-ANCA (-)	23		
MPO-ANCA (-), PR3-ANCA (+)	5		
MPO-ANCA (-), PR3-ANCA (-)	9		
C-reactive protein levels (mg/dl)			
range	2.8 - 14.1		
median	7.8		
Birmingham Vasculitis Activity Scores			
range	5 - 27		
median	14		
Involvement of other organs (n)			
Kidney	8		
Lung	12		
Skin	5		
Eye	4		
Hypertrophic pachymeningitis	6		
Facial palsy	2		
Mononeuropathy	8		
Systemic treatment (n)			


PSL(P)/CY	17
PSL(P)/RTX	8
PSL(P)/MTX	3
PSL(P)/AZA	4
PSL(P)	3
PSL	2


AAV; antineutrophil cytoplasmic antibody-associated vasculitis, GPA; granulomatosis with polyangiitis, MPA; microscopic polyangiitis, EGPA; eosinophilic granulomatosis with polyangiitis, ANCA; antineutrophil cytoplasmic antibody, MPO; myeloperoxidase, PR3; proteinase 3, PSL; prednisolone, (P); steroid pulse therapy, CY; cyclophosphamide, RTX; rituximab, MTX; methotrexate, AZA; azathioprine







a




b








a**b****c****d****e****f**

a



b



a**b****c**